Avanos Medical Acquires Nexus Medical to Strengthen Nutrition and Medication Delivery in Critical Care
Avanos Medical (NYSE: AVNS) has announced the acquisition of Nexus Medical, a private medical device company known for its proprietary TKO® anti-reflux needleless connector technology. The technology is specifically designed for safer nutrition and medication delivery in high-acuity settings like NICUs and PICUs.
The strategic acquisition enhances Avanos' Specialty Nutrition Systems business, particularly strengthening its position in neonatal patient care. The TKO® technology features a patented pressure-activated tri-seal silicone valve that reduces blood reflux issues during IV-based treatments.
The transaction was financed with available cash and is expected to be immediately accretive to revenue growth and earnings per share.
Avanos Medical (NYSE: AVNS) ha annunciato l'acquisizione di Nexus Medical, una società privata di dispositivi medici nota per la sua tecnologia proprietaria TKO® anti-reflux needleless connector. La tecnologia è specificamente progettata per una somministrazione di nutrizione e farmaci più sicura in contesti di alta intensità come NICU e PICU.
L'acquisizione strategica rafforza il ramo Specialty Nutrition Systems di Avanos, potenziando in particolare la sua posizione nell'assistenza neonatale. La tecnologia TKO® prevede una valvola in silicone a tre guarnizioni attivata dalla pressione, brevettata che riduce i problemi di reflusso ematico durante i trattamenti endovenosi.
La transazione è stata finanziata con liquidità disponibile e si prevede che sia immediatamente incrementale alla crescita dei ricavi e all'utile per azione.
Avanos Medical (NYSE: AVNS) ha anunciado la adquisición de Nexus Medical, una empresa privada de dispositivos médicos conocida por su tecnología propietaria TKO® anti-reflux needleless connector. La tecnología está diseñada específicamente para una entrega más segura de nutrición y medicamentos en entornos de alta exigencia como NICU y PICU.
La adquisición estratégica fortalece el negocio Specialty Nutrition Systems de Avanos, especialmente al reforzar su posición en el cuidado neonatal. La tecnología TKO® cuenta con una válvula de silicona de sellado triple activada por presión, patentada que reduce los problemas de reflujo sanguíneo durante tratamientos intravenosos.
La operación se financió con efectivo disponible y se espera que sea inmediatamente rentable para el crecimiento de ingresos y las ganancias por acción.
Avanos Medical (NYSE: AVNS)가 Nexus Medical를 인수했다고 발표했으며, 이는 독점적인 TKO® anti-reflux needleless connector 기술로 알려진 비상업용 의료기기 회사입니다. 이 기술은 NICU와 PICU와 같은 고밀도 환경에서 영양 공급과 약물 전달을 더 안전하게 설계되었습니다.
전략적 인수는 Avanos의 Specialty Nutrition Systems 사업을 강화하고 특히 신생아 환자 관리에서의 위치를 강화합니다. TKO® 기술은 압력 활성화 삼중 실리콘 밸브(특허 보유)를 특징으로 하며 IV 기반 치료 중 혈액 역류를 줄입니다.
거래는 사용 가능한 현금으로 조달되었으며 매출 성장과 주당순이익에 즉시 기여할 것으로 기대됩니다.
Avanos Medical (NYSE: AVNS) a annoncé l'acquisition de Nexus Medical, une société privée de dispositifs médicaux connue pour sa technologie propriétaire TKO® anti-reflux needleless connector. La technologie est spécifiquement conçue pour une livraison plus sûre de la nutrition et des médicaments dans des environnements à haute criticité comme les NICU et les PICU.
L'acquisition stratégique renforce le secteur Specialty Nutrition Systems d'Avanos, en renforçant particulièrement sa position dans les soins néonataux. La technologie TKO® est dotée d'une valve en silicone à triple joints actionnée par la pression, brevetée qui réduit les problèmes de reflux sanguin lors des traitements intraveineux.
La transaction a été financée par les liquidités disponibles et devrait être immédiatement contributive à la croissance des revenus et au bénéfice par action.
Avanos Medical (NYSE: AVNS) hat die Übernahme von Nexus Medical bekannt gegeben, einem privaten Medizingeräteunternehmen, das für seine proprietäre TKO® anti-reflux needleless connector-Technologie bekannt ist. Die Technologie ist speziell darauf ausgelegt, eine sicherere Verabreichung von Ernährung und Medikamenten in hochintensiven Umgebungen wie NICUs und PICUs zu ermöglichen.
Die strategische Akquisition stärkt das Geschäft Specialty Nutrition Systems von Avanos und festigt insbesondere die Position in der Versorgung von Neugeborenen. Die TKO®-Technologie verfügt über eine patentierte druckaktivierte Dreifach-Dichtungs-Silikonventil, das Blutrefluxprobleme bei IV-Behandlungen reduziert.
Die Transaktion wurde mit verfügbaren Mitteln finanziert und wird voraussichtlich sofort zum Umsatzwachstum und zum Ergebnis je Aktie beitragen.
Avanos Medical (NYSE: AVNS) أعلنت عن الاستحواذ على Nexus Medical، وهي شركة أدوات طبية خاصة معروفة بتقنيتها المملوكة TKO® anti-reflux needleless connector. تُصمم التقنية خصيصاً لتوفير تغذية وأدوية بشكل أكثر أماناً في بيئات عالية الحدة مثل وحدات العناية المركزة للأطفال الخدّج ووحدات العناية المركزة للأطفال.
يعزز هذا الاستحواذ الاستراتيجي قسم Specialty Nutrition Systems لدى Avanos، مع تقوية موقعها في رعاية المرضى حديثي الولادة. تتميز تقنية TKO® بـ صمام سيليكوني ثلاثي الختم يعمل بالضغط، وهو براءة اختراع يقلل من مشاكل ارتجاع الدم أثناء العلاجات الوريدية.
وقد تم تمويل الصفقة من خلال النقد المتاح ويتوقع أن تكون مساهمة فورية في نمو الإيرادات وربحية السهم.
Avanos Medical (NYSE: AVNS) 已宣布收购 Nexus Medical，这是一家以其专有的 TKO® anti-reflux needleless connector 技术 闻名的私人医疗器械公司。该技术专门为在 NICU 和 PICU 等高强度环境中的营养和药物输注提供更安全的解决方案。
此次战略收购增强了 Avanos 的 Specialty Nutrition Systems 业务，尤其强化了其在新生儿护理领域的地位。TKO® 技术具有一项 经专利的压力触发三重密封硅阀，在静脉治疗过程中降低血液反流问题。
交易以可用现金融资，预计将<立即有利于收入增长和每股收益。
- Immediate accretion to revenue growth and earnings per share
- Strategic expansion of Specialty Nutrition Systems business with complementary technology
- Strengthens market position in high-acuity care settings (NICU/PICU)
- Acquisition funded with available cash, indicating strong liquidity
- Integration costs and risks associated with merging operations
- Potential challenges in maintaining existing Nexus customer relationships during transition
Insights
Avanos' acquisition of Nexus Medical strengthens its NICU position with complementary technology while being immediately accretive to growth and EPS.
Avanos Medical's acquisition of Nexus Medical represents a strategic expansion of its critical care portfolio, specifically enhancing its Specialty Nutrition Systems business with complementary technology. The deal centers around Nexus's proprietary TKO® anti-reflux needleless connector technology, which addresses a critical clinical challenge in high-acuity settings like NICUs and PICUs.
The TKO® technology's patented tri-seal silicone valve tackles the problem of blood reflux during IV-based nutrition and medication delivery. This is particularly significant as reflux can lead to catheter occlusions, therapy delays, and increased infection risk – all serious concerns in neonatal care where precision and consistency are paramount.
From a financial perspective, the acquisition presents compelling economics. Avanos has financed the deal using
This acquisition aligns with Avanos's stated strategy of delivering "smarter, safer solutions across the critical care spectrum" and demonstrates its commitment to the high-value neonatal patient segment. By expanding its technological capabilities in this specialized area, Avanos strengthens its competitive positioning in a niche but crucial healthcare segment where clinical outcomes drive purchasing decisions.
Nexus is the maker of the proprietary TKO® anti-reflux needleless connector technology, designed to support safer, more consistent nutrition and medication delivery in high-acuity settings, including Neonatal and Pediatric Intensive Care Units (NICUs and PICUs).
The acquisition adds complementary technology to Avanos' Specialty Nutrition Systems business and reinforces the company's focus on safe, reliable therapy delivery for the neonatal patient population.
"This acquisition is a clear extension of our strategy to deliver smarter, safer solutions across the critical care spectrum," said Dave Pacitti, Avanos chief executive officer. "We are proud to add the Nexus TKO® technology and the full breadth of Nexus' offerings to our portfolio as we continue investing in meaningful innovation that helps clinicians provide consistent care and improve outcomes for patients who need it most."
The TKO® needleless connector features a patented, pressure-activated tri-seal silicone valve that minimizes blood reflux – a known contributor to catheter occlusions, therapy delays, and infection risk during IV-based nutrition and medication delivery.*
"Nexus TKO® fits naturally into our Specialty Nutrition Systems business and is expected to deliver immediate value in NICU and PICU care," said Kerr Holbrook, Avanos' chief commercial officer. "It's a practical, trusted solution that helps clinicians reduce disruptions and deliver therapy with greater consistency and ease."
Avanos financed the acquisition with available cash. The company expects the acquisition to be immediately accretive to both revenue growth and earnings per share.
About Avanos Medical
Avanos Medical (NYSE: AVNS) is a medical technology company focused on delivering clinically superior medical device solutions that help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, Avanos is committed to addressing some of today's most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures and markets its recognized brands globally and holds leading market positions in multiple product categories. For more information, visit www.avanos.com and follow Avanos Medical on X (@AvanosMedical), LinkedIn and Facebook.
About Nexus Medical
Founded in 2001, Nexus Medical invented the anti-reflux category in needleless connectors to solve the unintended consequences of blood reflux in IV catheters, including intraluminal thrombotic occlusions, catheter failure, and infections. As the most studied needleless connector on the market, the Nexus TKO® anti-reflux technology is an evidence-based way to simplify the complexity of IV therapy and improve patient safety. For more information, call (913) 451-2234 or visit www.nexusmedical.com.
*CLAIM ON FILE
View original content to download multimedia:https://www.prnewswire.com/news-releases/avanos-medical-acquires-nexus-medical-to-strengthen-nutrition-and-medication-delivery-in-critical-care-302555789.html
SOURCE Avanos Medical
FAQ
What company did Avanos Medical (AVNS) acquire in September 2025?
How will the Nexus Medical acquisition impact Avanos Medical's earnings?
What is the main technology acquired in the Avanos-Nexus Medical deal?
How did Avanos Medical finance the Nexus Medical acquisition?
What markets will benefit from the Avanos-Nexus Medical merger?
